Live

CellExpansion and CAR engineering of granulocyte-monocyte progenitors for cellular immunotherapy Endpoints NewsBiopharma’s LGBTQ+ leaders; Novo Nordisk hacked?; and more Science Daily BiotechThe secret language behind animal cooperation Endpoints NewsEndpoints News History: 10 Years, Bootstrap to FT Clinical OMICsImproving HSV-2 Vaccine Efficacy with Combination Strategy CellMultimodal imaging of gene expression, morphology, and activity of the same neuron 10x Genomics News10x Genomics, Cleveland Clinic Team Up on Bladder Cancer Diagnostics - Zacks Investment Research FierceBiotechFDA warning slams Zoll Medical with multiple quality control and reporting violations BioWorldHangzhou Innogate Pharma discovers new KAT inhibitors BioWorldAlicorn synthesizes new AAK1 inhibitors BioWorldChinese scientists identify new macrocyclic compounds as kinase inhibitors BioWorldNew VAV1 degradation inducers reported in Haisco Pharmaceutical Group patents

Archiv

Aktuell Älteste Löschen

Gesamt 62

Seite 3 / 4

Suche --

Endpoints News 24. März 2026

Merck partners with Flagship startup Quotient to search for genetic clues to IBD

BioWorld 6. März 2026

Cas and effect: Merck’s phase III ripples HIF-2α space

FierceBiotech 6. März 2026

Merck KGaA drops pipeline assets from SpringWorks buyout, Hengrui licensing deal

Endpoints News 5. März 2026

Merck KGaA drops two cancer trials on assets from SpringWorks deal

Merck KGaA 5. März 2026

Merck KGaA drops pipeline assets from SpringWorks buyout, Hengrui licensing deal - Fierce Biotech

BioWorld 26. Feb. 2026

MSD patent details new WRN inhibitors for cancer

Endpoints News 25. Feb. 2026

Gilead, Merck plan to debut new daily HIV pills

Endpoints News 23. Feb. 2026

Merck reorganizes; Blackstone to fund trials for J&J drug

BioPharma Dive 23. Feb. 2026

Merck to split cancer, specialty drug businesses in leadership shakeup

PharmaVoice 20. Feb. 2026

No one-trick pony in oncology, Merck’s cancer footprint is expanding

Endpoints News 19. Feb. 2026

Biogen stops part of an MS trial; Merck reports more Enflonsia data

BioPharma Dive 12. Feb. 2026

Sanofi, looking for more ‘rigor,’ swaps CEO Hudson for ex-Merck KGaA chief Garijo

FierceBiotech 12. Feb. 2026

Sanofi ousts Paul Hudson after ‘bumpy ride’, poaches Merck KGaA CEO to lead the French pharma

FierceBiotech 10. Feb. 2026

Merck teams up with British medtech to boost vaginal therapeutics delivery system

BioPharma Dive 13. Jan. 2026

JPM26: Biotech’s M&A lift, the ‘new’ Biogen and Merck’s $70B target

Endpoints News 12. Jan. 2026

FDA lifts partial hold on Merck, Daiichi's Phase 3 lung cancer study

BioPharma Dive 12. Jan. 2026

Eikon, a high-profile startup led by Merck vets, seeks an IPO

Endpoints News 9. Jan. 2026

How Merck plans to set a buffer for Keytruda's patent cliff